Saad Usmani1, Shaji K.Kumar2, Torben Plesner3, Robert Z.Orlowski4, Philippe Moreau5, Nizar Bahlis6, Supratik Basu7, Hareth Nahi8, Cyrille Hulin9, Hang Quach10, Hartmut Goldschmidt11, Michael O'Dwyer12, Aurore Perrot13, Christopher P.Venner14, Katja Weisel15, Joseph R.Mace16, Tahamtan Ahmadi17, Christopher Chiu18, Jianping Wang19, Rian van Rampelbergh20, Clarissa M.Uhlar18, Rachel Kobos19, Ming Qi18, Thierry Facon21
1Levine Cancer Institute / Atrium Health, 2Department of Hematology, Mayo Clinic Rochester, 3Vejle Hospital and University of Southern Denmark, 4Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, 5Hematology, University Hospital Hotel-Dieu, 6University of Calgary, Arnie Charbonneau Cancer Institute, 7Royal Wolverhampton Hospitals NHS Trust, 8Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, 9Department of Hematology, Hospital Haut Leveque, University Hospital, 10St. Vincent's Hospital, University of Melbourne, 11University Hospital Heidelberg and National Center of Tumor Diseases (NCT), 12Dept. of Medicine / Haematology, 13Hematology Department, University Hospital, 14Division of Medical Oncology University of Alberta, 15Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, 16Florida Cancer Specialists & Research Institute, 17Genmab US, Inc., 18Janssen Research & Development, Spring House, 19Janssen Research & Development, Raritan, 20Janssen Research & Development, Beerse, 21Service des Maladies du Sang, Hopital Claude Huriez
International Journal of Myeloma 9(1): 70-70, 2019.